A prolonged course of cyclophosphamide as an adjunct to mastectomy in the primary treatment of breast carcinoma.
Cyclophosphamide given after mastectomy for 4-6 months to a consecutive series of patients seen in one surgical practice in the years 1964 and 1965 significantly improved the 10-year survival rate of the treated patients as compared with the patients seen consecutively in the same surgical practice in the years 1957-63. Staging showed that the improvement was due to a significant increase in the survival rate in the patients with histologically negative axillary nodes (P less than 0-01). There was no significant difference in survival in the node positive or advanced disease groups.
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy; D011379:Prognosis
D003520:Cyclophosphamide